2227
document
Enalapril ( 10 mg/day ) in systemic sclerosis . One year , double blind , randomised study ( ESS-1 ) : echocardiographic substudy -- three months follow-up . The ESS-1 study was designed to evaluate the long-term effects of the angiotensin converting enzyme inhibitor ( ACEI ) enalapril ( 10 mg per day ) on the cardio-pulmonary system in patients with scleroderma ( SSc ) . We estimated changes in heart diameters , systolic and diastolic left ventricle function and mean values of pulmonary artery pressure after 3 months treatment . The study group comprise 41 patients with SSc . 18 patients received placebo and 23 ones were given enalapril . After 3 months of treatment we did not observe statistically significant differences in heart diameters and left ventricle systolic function parameters between treated group and placebo . Enalapril therapy did not affect left ventricle diastolic function , nevertheless differences in MVA were almost of statistical significance . Echocardiographic signs of pulmonary hypertension were found in 4 patients .
2228
Intervention_Pharmacological
Enalapril
2229
Intervention_Pharmacological
enalapril
2230
Intervention_Control
placebo
2231
Intervention_Pharmacological
enalapril
2232
Intervention_Pharmacological
Enalapril
2233
Outcome_Physical
heart diameters , systolic and diastolic left ventricle function and mean values of pulmonary artery pressure
2234
Outcome_Physical
heart diameters
2235
Outcome_Physical
left ventricle systolic function parameters
2236
Outcome_Physical
left ventricle diastolic function
2237
Outcome_Physical
MVA
2238
Outcome_Physical
pulmonary hypertension
2239
Participant_Condition
scleroderma ( SSc )
2240
Participant_Sample-size
41